TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
10.07
+1.49 (17.37%)
At close: Feb 5, 2026, 4:00 PM EST
10.00
-0.07 (-0.70%)
After-hours: Feb 5, 2026, 4:01 PM EST
TransCode Therapeutics Employees
TransCode Therapeutics had 7 employees as of December 31, 2024. The number of employees decreased by 3 or -30.00% compared to the previous year.
Employees
7
Change
-3
Growth
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,876,275
Market Cap
9.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 7 | -3 | -30.00% | 7 | 0 |
| Sep 30, 2024 | 8 | -2 | -20.00% | 8 | 0 |
| Dec 31, 2023 | 10 | -9 | -47.37% | 10 | 0 |
| Dec 31, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Dec 31, 2021 | 9 | 3 | 50.00% | 8 | 1 |
| Sep 30, 2021 | 7 | 1 | 16.67% | 7 | 0 |
| Jun 30, 2021 | 6 | 0 | - | 2 | 4 |
| Mar 31, 2021 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2020 | 6 | 0 | - | 2 | 4 |
| Sep 30, 2020 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| BiomX | 57 |
| Quince Therapeutics | 36 |
| SeaStar Medical Holding | 19 |
| CalciMedica | 15 |
| Kiora Pharmaceuticals | 12 |
| XTL Biopharmaceuticals | 10 |
| Revelation Biosciences | 9 |
RNAZ News
- 7 hours ago - TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 - PRNewsWire
- 4 weeks ago - TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma - PRNewsWire
- 6 weeks ago - TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - PRNewsWire
- 2 months ago - TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PRNewsWire
- 2 months ago - TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer - PRNewsWire
- 4 months ago - TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO - PRNewsWire
- 9 months ago - TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - PRNewsWire
- 9 months ago - TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - PRNewsWire